Business Wire

Grindr Launches In-App Access to Sexual Health and Safety Resources in 30 Countries Around the World

11.7.2024 16:00:00 EEST | Business Wire | Press release

Share

Grindr Inc. (NYSE:GRND), the premier LGBTQ+ social connector, today announced it has partnered with several organizations to launch in-app access to sexual health and safety resources for its users in 30 countries around the world. This wide-reaching program is led by Grindr for Equality, the company’s social impact initiative. Grindr users across 30 countries, including Brazil, Kenya, Spain, and Namibia, are now able to access these vital sexual health and safety resources directly through a side drawer on the Grindr app’s home screen, gaining localized and real-time information on the issues that matter to them the most.

Since 2015, Grindr for Equality has worked towards a world where the lives of Grindr users and the global LGBTQ+ community are free, equal, and just, advancing initiatives that impact communities on issues such as safety and sexual health. Lack of access to HIV testing is one of the biggest obstacles in the fight against the global HIV epidemic, posing a particular burden for some Grindr users, such as those living in rural areas or those who are not “out” to their families. Additionally, anti-LGBTQ+ legislation threatens the safety of members of the queer community every day by criminalizing their fundamental identities. With its new partnerships and its ongoing work, Grindr for Equality aims to empower users with real-time access to critical information that helps combat this adversity.

The new safety and sexual health resources available on the Grindr platform are led by Grindr for Equality’s partnership with European Test Finder, a free online tool that helps users find nearby locations for testing and treatment of HIV, Tuberculosis, Hepatitis B and C, and other STIs across the WHO European region. Grindr users across 24 countries supported by European Test Finder, including Austria, Belgium, Cyprus, France, Serbia, Slovakia, and Ukraine, are now able to quickly access vital public health services directly on Grindr. Grindr for Equality is also partnering with Ceska spolecnost aids pomoc, IntraHealth Namibia, IVOR Foundation, and The Love Tank to make additional sexual and mental health resources available to Grindr users in Czechia, Namibia, Bulgaria, and the United Kingdom, respectively.

In Brazil, Grindr for Equality is partnering with Ministério da Saúde, Departamento de HIV, Aids, Tuberculose, Hepatites Virais e Infecções Sexualmente Transmissíveis to provide in-app access to Onde encontrar a PrEP, a PrEP service locator. Grindr for Equality is also partnering with GALCK+ to provide Grindr users in Kenya with in-app access to Know Your Rights, a safety page designed to empower the Kenyan LGBQ community by informing them of their rights.

“Grindr is proud to partner with groups like CHIP and the EuroTEST Initiative that are hosting the European Test Finder to increase access to essential sexual health and safety resources for users around the world,” said Steph Niaupari of Grindr for Equality. “We’ve seen how in-app resources can help drive meaningful public health outcomes for the LGBTQ+ community, and we look forward to expanding the impact Grindr is able to achieve by providing a wider range of sexual health and safety resources to more of our global users.”

“We are thrilled to partner with Grindr to widen access to crucial testing and treatment for life-altering conditions such as HIV, Tuberculosis, and Hepatitis,” said Cæcilie Bom Kahama, project coordinator for the European Test Finder, at the secretariat of the EuroTEST Initiative, at CHIP in Denmark. “By helping more individuals quickly and easily access these public health services, Grindr is taking concrete steps to promote early diagnosis and care. We are grateful for the company’s leadership on this matter and hope this will encourage more people to test regularly and ultimately help reduce overall transmission.”

Today’s announcement builds on the success of Grindr for Equality’s existing partnerships to distribute free at-home HIV test kits directly to Grindr users across a growing list of countries including Georgia, Ireland, New Zealand, and the United States, as well as the City of London. In partnership with organizations including Building Healthy Online Communities, these programs have distributed more than 440,000 test kits to date. Grindr for Equality plans to launch similar initiatives and bring additional safety, sexual health, and advocacy resources to more Grindr users and members of the LGBTQ+ community around the world.

About Grindr Inc.

With more than 13.7 million monthly active users, Grindr has grown to become the Global Gayborhood in Your Pocket, on a mission to make a world where the lives of our global community are free, equal, and just. Available in 190 countries and territories, Grindr is often the primary way for its users to connect, express themselves, and discover the world around them. Since 2015 Grindr for Equality has advanced human rights, health, and safety for millions of LGBTQ+ people in partnership with organizations in every region of the world. Grindr has offices in West Hollywood, the Bay Area, Chicago, and New York. The Grindr app is available on the App Store and Google Play.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240711785938/en/

Contacts

Media:
Press@grindr.com

Investors:
IR@grindr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye